Cas:17899-47-7 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride manufacturer & supplier

Chemical Name:4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride

CAS.NO:17899-47-7

Synonyms:4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride

Molecular Formula:C₆H₁₁Cl₂N₃S

Molecular Weight:228.14300

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:79.18000

Exact Mass:227.00500

LogP:2.88500

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride Use and application,4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride technical grade,usp/ep/jp grade.

Related News: He was the partner of a 38-year-old Chinese woman who was travelling with him. She was the first confirmed case reported in the Philippines. 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride manufacturer In addition, the FDA approval ignored the recommendation of its outside advisors, who said Biogen did not provide enough evidence of clinical benefit. Three of the advisory panel’s members have resigned in protest since the FDA decision was announced on Monday. 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride supplier Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride vendor Retrogenix and Resonant Therapeutics, Inc. recently announced they have entered into a non-exclusive strategic partnership to identify the targets of Resonant antibodies directed against the tumor microenvironment. 4,5,6,7-tetrahydro-[1,3]thiazolo[5,4-c]pyridin-2-amine,dihydrochloride factory The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.